The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.

The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.

The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.

The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.

The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.

The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.

The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.

The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.